Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA─positive mCRPC
Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who …